English
English
English
New Delhi: Polycystic Ovary Syndrome has long been recognised as a leading hormonal disorder affecting women of reproductive age worldwide. Alongside Polycystic Ovarian Disease (PCOD), it is frequently linked with irregular menstrual cycles and fertility challenges. However, medical experts emphasise that the two conditions differ in severity and systemic impact.
PCOD is generally considered a milder condition, primarily affecting ovarian function. It involves the development of multiple immature follicles in the ovaries, often triggered by lifestyle factors such as stress, poor diet and inactivity. Ovulation may still occur, and symptoms are often manageable with lifestyle modification.
By contrast, PCOS is now understood as a complex endocrine and metabolic disorder. It is associated with elevated androgen levels, insulin resistance, weight gain, acne, and excess hair growth. The condition can disrupt ovulation and significantly increase long-term risks of diabetes, cardiovascular disease and other metabolic complications.
Recent scientific discussions, including a consensus highlighted in The Lancet, have proposed renaming PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change aims to better represent the condition’s multi-system nature and move beyond the misleading focus on ovarian cysts alone.
Researchers stress that insulin resistance and chronic inflammation are central to the disorder, influencing both reproductive and metabolic health. Early recognition and intervention are considered crucial for preventing complications such as type 2 diabetes and cardiovascular issues.
Management strategies differ between PCOD and PCOS. PCOD often responds well to dietary improvements, regular exercise and stress management techniques. In contrast, PCOS or PMOS usually requires a combination of lifestyle changes and medical therapies targeting hormonal imbalance and insulin sensitivity.
Experts continue to encourage clearer awareness of these distinctions to reduce confusion in diagnosis and treatment. Improved understanding is expected to support earlier screening, better metabolic assessment and more personalised care for affected women globally. While PCOD is largely reversible with consistent lifestyle adjustments, PCOS or PMOS remains a long-term condition requiring ongoing clinical monitoring and multidisciplinary care.
Growing attention in medical literature reflects a shift toward recognising hormonal, metabolic and endocrine links rather than focusing solely on ovarian structure. This evolving perspective is expected to improve outcomes and reduce the global burden of reproductive and metabolic disorders associated with PCOS. Awareness campaigns and ongoing research continue to evolve worldwide in healthcare systems.
